The combination of Zoll Medical and Itamar Medical would help strengthen the collaboration between the worlds of cardiology and sleep medicine, Jon Rennert, Zoll’s CEO said.
Zoll Medical Corp. announced on 13 September plans to acquire Itamar Medical Ltd. for a total value of $538m, or $1.09 per ordinary share, which will add Itamar’s home-based testing for sleep apnea to Zoll’s cardiopulmonary product offerings.
SVB Leerink Research analyst Richard Newitter wrote in his flash report that the deal “looks to us like a good strategic fit for both companies.”
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
